Table VI.
Thrombotic events, IPSET-T score and treatment response of essential thrombocythemia patients stratified by their mutation status of CALR, JAK2 and MPL.
| Parameter | TN (n=28) | CALR-mutant (n=23) | JAK2 V617F-mutant (n=21) | P-value |
|---|---|---|---|---|
| Thrombosis/thromboembolism | 5 (17.9) | 5 (21.7) | 3 (14.3) | 0.864 |
| IPSET-T score | 0.001 | |||
| Low-risk (0–1) | 22 (78.6) | 18 (78.3) | 0 (0) | |
| Intermediate-risk (2) | 4 (14.3) | 0 (0) | 7 (33.3) | |
| High-risk (≥3) | 2 (7.1) | 5 (22.7) | 14 (66.7) | |
| Treatment response | 0.015 | |||
| CR | 9 (32.1) | 5 (21.7) | 13 (61.9) | |
| PR | 11 (39.3) | 10 (43.5) | 6 (28.6) | |
| NR | 8 (28.6) | 8 (34.8) | 2 (9.5) |
Values are expressed as n (%). CR, complete response; PR, partial response; NR, no response; TN, triple-negative; JAK, Janus kinase; CALR, calreticulin; IPSET-T, International Prognostic Scoring for ET thrombosis; ET, essential thrombocythemia.